BACKGROUND: In eukaryotic cells, the cytoskeleton contains three major filamentous components: actin microfilaments, microtubules and intermediate filaments. Nestin represents one of the class VI intermediate filament proteins. Clinical and molecular analyses have revealed substantial information regarding the presence of Nestin in cells with progenitor or stem cell properties. During tissue injury Nestin is expressed in cells with progenitor cell-like properties. These cells may serve as a tissue reserve and, as such, may contribute to tissue repair. Based on currently available data, Nestin also appears to be implicated in two oncogenic processes. First, Nestin has been found to be expressed in cancer stem-like cells and poorly differentiated cancer cells and, as such, Nestin is thought to contribute to the aggressive behavior of these cells. Second, Nestin has been found to be involved in tumor angiogenesis through an interaction of cancer cells and blood vessel endothelial cells and, as such, Nestin is thought to facilitate tumor growth. CONCLUSIONS: We conclude that Nestin may serve as a promising tumor marker and as a potential therapeutic target amenable to tumor suppression and angiogenesis inhibition.
BACKGROUND: In eukaryotic cells, the cytoskeleton contains three major filamentous components: actin microfilaments, microtubules and intermediate filaments. Nestin represents one of the class VI intermediate filament proteins. Clinical and molecular analyses have revealed substantial information regarding the presence of Nestin in cells with progenitor or stem cell properties. During tissue injuryNestin is expressed in cells with progenitor cell-like properties. These cells may serve as a tissue reserve and, as such, may contribute to tissue repair. Based on currently available data, Nestin also appears to be implicated in two oncogenic processes. First, Nestin has been found to be expressed in cancer stem-like cells and poorly differentiated cancer cells and, as such, Nestin is thought to contribute to the aggressive behavior of these cells. Second, Nestin has been found to be involved in tumor angiogenesis through an interaction of cancer cells and blood vessel endothelial cells and, as such, Nestin is thought to facilitate tumor growth. CONCLUSIONS: We conclude that Nestin may serve as a promising tumor marker and as a potential therapeutic target amenable to tumor suppression and angiogenesis inhibition.
Authors: Shideng Bao; Qiulian Wu; Zhizhong Li; Sith Sathornsumetee; Hui Wang; Roger E McLendon; Anita B Hjelmeland; Jeremy N Rich Journal: Cancer Res Date: 2008-08-01 Impact factor: 12.701
Authors: Rohan K Humphrey; Nathan Bucay; Gillian M Beattie; Ana Lopez; Conrad A Messam; Vincenzo Cirulli; Alberto Hayek Journal: Diabetes Date: 2003-10 Impact factor: 9.461
Authors: Sophia R Bloch; Nguyen T K Vo; Sarah K Walsh; Cici Chen; Lucy E J Lee; Peter V Hodson; Niels C Bols Journal: In Vitro Cell Dev Biol Anim Date: 2015-12-29 Impact factor: 2.416
Authors: Lap Hing Chi; Ryan S N Cross; Richard P Redvers; Melissa Davis; Soroor Hediyeh-Zadeh; Suresh Mathivanan; Monisha Samuel; Erin C Lucas; Kellie Mouchemore; Philip A Gregory; Cameron N Johnstone; Robin L Anderson Journal: Oncogenesis Date: 2022-07-11 Impact factor: 6.524